TCR-T therapy has been developed for over 20 years, and multiple preclinical studies have shown that TCR-T therapy targeting tumor-specific antigens such as MAGE and GP100 has certain efficacy in melanoma, colorectal cancer, and synovial sarcoma 10, but clinical trials of TCR-T for TNBC treatment are relatively few. Here, TBXT is linked to melanoma.